Erbb2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country by García Molina, Mario et al.
Rev. salud pública. 16 (2): 270-280, 2014
270
ErbB2+metastatic breast cancer 
treatment after progression on 
trastuzumab: a cost-effectiveness 
analysis for a developing country
Tratamientos para cáncer de seno metastásico ErbB2+ en 
progresión Post-Trastuzumab: Análisis de costo-efectividad para 
un país en vía de desarrollo
Liliana Chicaíza-Becerra1, Mario García-Molina1, 
Oscar Gamboa2 y Carlos Castañeda-Orjuela1
1 Universidad Nacional de Colombia, Bogotá, Colombia. lachicaizab@unal.edu.co; mgarciamo@
unal.edu.co; cacastanedao@unal.edu.co
2 Instituto Nacional de Cancerología, Bogotá, Colombia. oa_gamboa@yahoo.es
Received 7th August 2012/Sent for Modification 15th October 2013/Accepted 18th November 2013
ABSTRACT
Objective Breast cancer (BC) and metastatic breast cancer (MBC) are significant 
causes of deaths amongst women worldwide, including developing countries. 
The cost of treatment in the latter is even more of an issue than in higher income 
countries. ErbB2 overexpression is a marker of poor prognosis and the goal for 
targeted therapy. This study was aimed at evaluating the cost-effectiveness in 
Colombia of ErbB2+ MBC treatment after progression on trastuzumab.
Methods A decision analytic model was constructed for evaluating such treatment 
in a hypothetical cohort of ErbB2+MBC patients who progressed after a first scheme 
involving trastuzumab. The alternatives compared were lapatinib+capecitabine 
(L+C), and trastuzumab+a chemotherapy agent (capecitabine, vinorelbine or a 
taxane). Markov models were used for calculating progression-free time and the 
associated costs. Effectiveness estimators for such therapy were identified from 
primary studies; all direct medical costs based on national fees-guidelines were 
included. Sensitivity was analyzed and acceptability curves estimated. A 3 % 
discount rate and third-payer perspective were used within a 5-year horizon. 
Results L+C dominated its comparators. Its cost-effectiveness ratio was COP 
$49,725,045 per progression-free year. The factors most influencing the results 
were the alternatives’ hazard ratios and the cost of trastuzumab.
Conclusion Lapatinib was cost-effective compared to its alternatives for treating 
MBC after progression on trastuzumab using a Colombian decision analytic model.
Key Words: Cost-benefit analysis, breast neoplasm, receptor, epidermal growth 
factor, Colombia (source: MeSH, NLM).
Chicaíza - Metastatic breast cancer: a cost-effectiveness analysis 271
RESUMEN
Objetivo El cáncer de seno (CS) y cáncer de seno metastásico (CSM) son importantes 
causas de muerte entre las mujeres a nivel mundial y en países en vía de desarrollo. 
En estos últimos los costos de los tratamientos son aún más preocupantes que en 
países de alto ingreso. La sobreexpresión de ErbB2 es marcador de pobre pronóstico 
y objetivo de terapias dirigidas. Se evaluó la costo-efectividad de los tratamientos de 
CSM ErbB2+ en progresión post-trastuzumab en Colombia.
Métodos Se desarrolló un modelo analístico de decisiones para evaluar los tra-
tamientos en una cohorte hipotética de CSM ErbB2+ que progresaron después 
de un primer esquema con trastuzumab. Las alternativas comparadas fueron: 
lapatinib+capecitabina (L+C), y trastuzumab más un agente quimioterápico (ca-
pecitabina, vinorelbinao un taxano). Se usaron modelos de Markov para calcular 
el tiempo libre de progresión y los costos asociados. Estimaciones de efectividad 
fueron identificadas de estudios primarios. Se incluyeron todos los costos médi-
cos directos basados en los manuales tarifarios nacionales. Se realizaron análisis 
de sensibilidad y curvas de aceptabilidad. Se descontaron costos y resultados 
a una tasa anual de 3 %, la perspectiva de análisis fue del tercer pagador y el 
horizonte de 5 años.
Resultados L+C domina a sus comparadores con un razón de costo-efectividad 
de COP $49 725 045 por año libre de progresión. Los factores que más influencian 
los resultados son los hazard ratios de las alternativas y el costo de trastuzumab.
Conclusión Lapatinib es costo-efectivo comparado con sus alternativas para el 
tratamiento del CSM después de la progresión con trastuzumab en el escenario 
colombiano.
Palabras Clave: Análisis de costo-beneficio, cáncer de seno, receptores del factor 
de crecimiento epidérmico, Colombia (fuente: DeCS, BIREME).
Around 45 % of the more than 1 million breast cancer (BC) diagnoses and 55 % of BC-related deaths every year occur in developing countries (1). The 5-year recurrence-free mean survival rate 
worldwide is 60 % (2). Almost 50 % of BC patients develop metastatic 
disease (3). Retrospective analysis shows a decrease in metastatic breast 
cancer (MBC) incidence (4) and longer survival due to the introduction 
of new agents and targeted therapy (5); however, such tendency may be 
hindered in developing countries due to their lower income and other 
urgent health-related problems, such as infectious diseases.
MBC treatment is not seen as being curative but mainly palliative, 
concentrating on an improvement in the progression-free survival and 
patients’ quality of life (6).
Due to the development of inactivating-only targeted drugs, epidermal 
REVISTA DE SALUD PÚBLICA · Volumen 16 (2), Abril 2014272
growth factor receptors (EGFR) and hormone receptors represent significant 
biological markers in BC and MBC treatment. EGFRs (ErbB1 and ErbB2) 
have been found to be overexpressed in around 25 % of primary BC (7-
10); it is associated with poor prognosis (lower recurrence-free (RF) and 
overall survival (OS) rates) (7-12).
Trastuzumab alone or combined with first-line chemotherapy in phase 
III clinical trials has given better overall response (OR), time to progression 
(TP) and OS rates than chemotherapy alone in ErbB2+MBC patients (13-
16). Evidence of trastuzumab use in Erb B2+MBC which has progressed 
after trastuzumab-based therapy mainly consisted of retrospective analysis 
and limited-sized phase II studies (17-30). One phase III study (31-32) 
found that trastuzumab + capecitabine had better OR, clinical benefit (CB) 
and TP rates than capecitabine alone.
Lapatinib is an oral, small molecule which selectively and reversibly 
inhibits the tyrosine-kinase signalling pathways for ErbB2+ErbB1 and 
EGFR which are useful in MBC cases where resistance to trastuzumab has 
developed (18, 29). L+C has been shown to be superior to capecitabine alone 
in patients who have previously been treated with trastuzumab (33-34). 
This study was aimed at assessing the cost-effectiveness of L+C compared 
to trastuzumab plus chemotherapy for ErbB2+MBC in Colombia. 
MATERIALS AND METHODS
The alternatives assessed here were (L+C) compared to trastuzumab 
+ capecitabine (T+C), trastuzumab + paclitaxel (T+P), trastuzumab + 
docetaxel (T+D), and trastuzumab + vinorelbine (T+V). Trastuzumab-
based strategies represent current practice in Colombia, although the 
different alternatives coexist.
A three-state Markov model for the natural history of MBC was 
constructed (Figure 1). The model simulated a cohort of MBC women 
whose cancer had already progressed after a trastuzumab first scheme. 
Initial state was called progression free survival (PFS). Patients were 
treated with L+C or trastuzumab plus chemotherapy, according to the 
alternative, until they progressed again (and moved on to the progression 
(P) state). Only palliative care was administered from then on.
Indirect comparisons were made in the absence of head-to-head studies. 
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The sources of evidence for estimating probability were the ErbB2+ 
subgroups of clinical trials comparing T+C to capecitabine (32) and L+C to 
capecitabine (33). Disease-free survival (DFS) and OS rates were estimated 
as Weibull functions for each chemotherapy alone from the survival curves 
reported in the literature and multiplied by the hazard ratios (HR) from 
trastuzumab and lapatinib studies. 
Figure 1. Markov model, natural history of MBC
Progression
f- ree
survival
Progression
Death
Table 1. Parameters for the model
Estimation Average Standard Error Distribution Source
Weibull parameters survival functions DFS
Capecitabine monotherapy
Lambda
Gamma
HR Lapatinibpluscapecitabinevs. 
Capecitabinemonotherapy
HR Trastuzumabpluscapecitabinevs. 
Capecitabine monotherapy
OS
0.0053
1.25
0.59
0.685
0.125
0.1244
Bootstrap
Bootstrap
Lognormal
Lognormal
Geyer (33)
Von Minckwitz 
G (32)
Lapatinibpluscapecitabine
Lambda
Gamma
0.0019
1.61
Bootstrap
Bootstrap Geyer (33)HR Lapatinib + capecitabinevs 
capecitabinemonotherapy 0.92 0.27 Lognormal
HR Trastuzumabpluscapecitabinevs. 
capecitabinemonotherapy 0.763 0.1882 Lognormal
Von Minckwitz 
G (32)
PSA: probabilistic sensitivity analysis
The models supposed all types of chemotherapy to be equally effective, 
only differing regarding their cost and adverse events. Table 1 gives the 
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parameters used in the model and their sources.
ErbB2+metastatic breast cancer care protocols and adverse events in 
a Colombian setting were validated by peer consensus. Direct care costs 
were identified for each event based on the Colombian Social Protection 
Ministry’s SISPRO database drug cost information system and national 
fees guidelines (SOAT 2009) (Table 2).
Progression-free time was the outcome and discount rate 3 %. The 
perspective adopted was that of the third payer, including all direct medical 
costs. The time horizon was 5 years. Incremental cost-effectiveness ratios 
were calculated. Deterministic and probabilistic sensitivity analysis 
included acceptability curves for each alternative.
Table 2. Data used in the model
Generic name Pharmaceutical form Strength Cost 2009 Dose
Trastuzumab Infusion lyophilized powder container by vial 440 mg
COP 
$6,926,888.00
2mg/Kg IV weekly until 
progression evidence
Lapatinib Ditosylate 
Monohydrate
Coated tablet container 
by 70 tablets 250 mg
COP 
$47,630.14 1250 mg daily
Capecitabine Tablet (folding container by 8 tablets) 500 mg
COP 
$18,484.11
14 days cycles 2000 mg/
m2SC daily with washout for 
7 days
Vinorelbine Vial 50 mg/ 50 mL 50 mg COP $363,050.80
25mg/m2SC weekly for two 
weeks, washout the third 
week and then restarting
Paclitaxel Vial 100 mg/ 16.7 mL 100 mg COP $169,718.84
175 mg/m2SC once every 
three weeks for six cycles
Docetaxel
Vial 20 mg / 0.5 mL 
(Container with one 
ampoule)
20 mg COP $97,155.87
35 mg/m2SC weekly for 
three weeks, with washout 
the fourth week and then 
restarting
RESULTS
L+C was the most effective and least expensive alternative (i.e. dominant) 
(Table 3). L+C cost-effectiveness ratio was COP $49,725,045 per 
progression-free year (average Colombian exchange rate in 2009 was COP 
$2,156 per dollar).
Four variables accounted for 99.4 % of variability in the results: T+C 
cf capecitabine OS and DFS HR, L+C cf capecitabine OS and the cost 
per vial of trastuzumab (Figure 2). Tornado analysis results for the other 
alternatives were very similar (data not shown).
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A probabilistic sensitivity analysis with 10,000 simulations (Figure 
3) showed that L+C was dominant for 50.13 % of the simulations and 
was still cost-effective in the remaining 49.87 % cases, as the ICER for 
the alternatives exceeded the three times per-capita GDP threshold (three 
times COP $11,216,656). Similar results were produced when trastuzumab 
was accompanied by taxane or vinorelbine (data not shown).
Table 3. Cost-effectiveness analysis
Strategy Cost Incremental Cost Effectiveness
Incremental 
effectiveness CE ICER
L+C COP $82,017,207 1.649
COP 
$49,725,045
T+C COP $111,679,005
COP 
$29,661,798 1.631 -0.018
COP 
$68,442,394 Dominated
T+P COP $100,284,893
COP $ 
18,267,686 1.631 -0.018
COP 
$61,459,521 Dominated
T+D COP $ 104,594,593
COP 
$22,577,386 1.631 -0.018
COP 
$64,130,406 Dominated
T+ V COP $ 105,313,611
COP 
$23,296,404 1.631 -0.018
COP $   
64,541,367 Dominated
Figure 2. Tornado diagram at T+C vs. L+C.
Colombian pesos per progression-free year for T+C vs. L+C
GS HR L+C vs. capecitabine: 0.6 to 0.94
DFS HR T+C vs. capecitabine: 0.482 to 0.974
- $17M - $7M $3M $13M $24M
Annual discount rate cost: 0 to 0.06
Cost pill capecitabine: COP$13,863 to COP$23,105
Annual discount rate eect: 0.035 to 0.06
Cost pill lapatinib: COP$35,722 to COP$59,307
DFS HR L+C vs. capecitabine: 0.4 to 0.74
Cost per vial trastuzumab: COP$6,281,514 to COP$10,469,356
GS HR T+C vs. capecitabine: 0.477 to 1.2
DISCUSSION
This cost-effectiveness analysis showed that the lapatinib-based strategy 
was dominant in MBC treatment after ErbB2+ progression on trastuzumab 
compared to trastuzumab with capecitabine, taxane or vinorelbine. 
A benefit not included in this analysis was that the lapatinib strategy only 
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required oral administration, implying a positive impact on patients’ quality 
of life. A cost-utility analysis was not made as there are no evaluations 
of states of health have been made in Colombia; instead, the result was 
expressed in DFP years because OS was not significantly different in the 
alternatives. 
Figure 3. Probabilistic sensitivity analysis
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ICE: incremental cost effectiveness
Our analysis did not include other strategies as comparators because 
they are not accepted in Colombia as oncological treatment. The results 
were subject to commercial and regulatory practice determining the prices 
and packing-sizes used in Colombia.
Although there was no cost-effectiveness threshold for Colombia, we 
used WHO recommendations in terms of annual per capita GDP; however, 
as lapatinib dominated the alternatives currently being used in Colombian 
medical practice, the result was robust regarding the threshold.
This study’s limitations included treatment-effectiveness data being 
obtained from international studies which obviously used different 
populations to the Colombian population. If treatment effectiveness and 
complication frequency were significantly different from that considered in 
this study, the results would also have been different. Given a lack of head-
to-head studies comparing the alternatives being studied, the comparisons 
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in this analysis were indirect and based on HRs from existing randomized 
clinical trials; the results would thus vary for direct comparison. Due to 
data being unavailable for determining chemotherapy effectiveness, a 
strong assumption was required in taking the same effectiveness, implying 
that therapy would differ only regarding cost and adverse events.
Prior economic analysis has dealt with trastuzumab in ErbB2+MBC 
progression (35-46) but only two have compared it to L+C (47, 48). One 
found that L+C ICER exceeded the threshold per QALY gained for the 
USA; the other found that L+C was dominant for the UK, as it provided 
greater QALY at lower cost compared to T+C or T+V or trastuzumab only. 
Another analysis comparing L+C cf T+C for Mexico (49) was based on 
results from an interrupted clinical trial (50). So far no full-length article 
has been published for a developing country. This is the first complete cost-
effectiveness analysis comparing two human epidermal growth receptor 
inhibitors in advanced MBC for a developing country.
Current trastuzumab-based practice relies on using the same treatment, 
even after patients have developed resistance to it. Developing countries 
must have access to cost-effective alternatives thereby enabling 
ErbB2+metastatic breast cancer to be faced while keeping the fiscal burden 
at bay ●
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